TiGenix (BEL)

TiGenix NV (NYSE Euronext: TIG) is a leading European cell therapy company with two marketed products and a strong clinical stage pipeline of adult stem cell programs. The company’s lead product, ChondroCelect®, for cartilage repair in the knee, is the only approved cell-based product in Europe, and is currently being launched across Europe.

TiGenix’s adipose derived allogeneic stem cell platform has been extensively validated. The company is preparing a Phase III clinical trial to treat complex perianal fistula in patients with Crohn’s, has a Phase IIa trial in rheumatoid arthritis ongoing, and will start a Phase I trial to investigate intra-lymphatic administration in autoimmune disorders.

TiGenix is based out of Leuven (Belgium) and has operations in Madrid (Spain), Cambridge (UK) and Sittard-Geleen (the Netherlands). For more information please visit www.tigenix.com.